Exagen (NASDAQ:XGN) Given New $10.00 Price Target at BTIG Research

Exagen (NASDAQ:XGN) had its price objective trimmed by BTIG Research from $15.00 to $10.00 in a research note published on Tuesday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

Several other brokerages have also issued reports on XGN. Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, January 21st. B. Riley Financial reaffirmed a “buy” rating and issued a $8.00 price target (down from $18.00) on shares of Exagen in a research note on Friday, January 30th. Finally, Canaccord Genuity Group increased their price objective on Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $11.67.

Exagen Trading Up 0.9%

Shares of XGN opened at $3.31 on Tuesday. Exagen has a 1-year low of $2.67 and a 1-year high of $12.23. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 1.35. The firm’s 50-day moving average price is $5.16 and its 200-day moving average price is $8.16. The firm has a market capitalization of $75.00 million, a price-to-earnings ratio of -3.60 and a beta of 1.90.

Hedge Funds Weigh In On Exagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new stake in shares of Exagen in the 1st quarter worth $25,000. Truvestments Capital LLC boosted its position in shares of Exagen by 109.5% during the fourth quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after buying an additional 3,225 shares during the last quarter. Persistent Asset Partners Ltd bought a new stake in Exagen in the 4th quarter worth about $80,000. Schonfeld Strategic Advisors LLC purchased a new position in Exagen in the 4th quarter worth about $82,000. Finally, Jain Global LLC bought a new position in Exagen during the 4th quarter valued at about $82,000. 75.25% of the stock is owned by institutional investors.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.